Company profile: Amplitude Vascular Systems
1.1 - Company Overview
Company description
- Provider of intravascular lithotripsy devices to treat calcified arterial disease, featuring the PULSE IVL System that uses pressure waves via a balloon platform to fracture plaque and expand stenotic lesions, with applications in peripheral (above-knee, femoropopliteal) and coronary arteries, plus the Pulse IVL Console and ergonomic Handle for optimized energy delivery and clinician interaction.
Products and services
- PULSE IVL™ System: Engineers intravascular lithotripsy using pressure waves to fracture vascular calcium and expand stenotic lesions in calcified arteries via a balloon-based platform
- Clinical Applications of PIVL™ for Coronary Artery Disease: Delivers coronary-specific therapy that shatters calcium and expands vessels, extending PULSE IVL™ capabilities to calcified coronary artery disease
- Clinical Applications of PIVL™ for Peripheral Artery Disease: Supplies femoropopliteal-focused treatment for severely calcified lesions above the knee and in the femoropopliteal artery using the PULSE IVL™ System
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amplitude Vascular Systems
Huinno
HQ: South Korea
Website
- Description: Provider of AI-enabled wearable cardiac monitoring solutions: MEMO Solution and MEMO Patch 2 for 14-day continuous ECG monitoring; MEMO Care, a web platform for patient management with cloud ECG storage/analysis; MEMO Link, a gateway transmitting real-time biometric data to avoid network disruptions in emergencies; and MEMO Q for remote patient monitoring and ECG/biometric diagnostics, helping prevent arrhythmia, stroke, and hypertension.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Huinno company profile →
Ancora Heart
HQ: United States
Website
- Description: Provider of the AccuCinch Ventricular Restoration System, a minimally invasive therapy for heart failure patients with reduced ejection fraction, aiming to reduce the size of the left ventricle and support its wall, and the CORCINCH-HF clinical study evaluating the safety and efficacy of AccuCinch in patients with symptomatic heart failure and reduced ejection fraction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ancora Heart company profile →
Invatec
HQ: United States
Website
- Description: Provider of interventional coronary and peripheral products, focused on the development and commercialization of research-driven technologies. Headquartered in Europe, the company collaborates with physicians and centers of excellence to create products aimed at improving life expectancy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Invatec company profile →
Bacchus Vascular
HQ: United States
Website
- Description: Provider of medical devices for treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States, including the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter enabling targeted delivery to treat deep vein thrombosis and arterial occlusions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bacchus Vascular company profile →
Omeicos
HQ: Germany
Website
- Description: Provider of first-in-class small-molecule therapeutics based on omega-3 fatty acid metabolites for the treatment and prevention of atrial fibrillation and broader indications. Offers OMT-28, a synthetic analog of 17,18-EEQ for cardiovascular inflammation and mitochondrial dysfunction; conducts the PMD-OPTION study in Primary Mitochondrial Disease; and develops a pipeline of proprietary omega-3 analogs for cardiovascular, inflammatory, and mitochondrial diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeicos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amplitude Vascular Systems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amplitude Vascular Systems
2.2 - Growth funds investing in similar companies to Amplitude Vascular Systems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amplitude Vascular Systems
4.2 - Public trading comparable groups for Amplitude Vascular Systems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →